Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinic

Despite FDA approval of nine new drugs for patients with acute myeloid leukemia (AML) in the United States over the last 4 years, AML remains a major area of unmet medical need among hematologic malignancies. In this review, we discuss the development of promising new molecular targeted approaches for AML, including menin inhibition, novel IDH1/2 inhibitors, and preclinical means to target TET2, ASXL1, and RNA splicing factor mutations. In addition, we review progress in immune targeting of AML through anti-CD47, anti-SIRP alpha, and anti-TIM-3 antibodies; bispecific and trispecific antibodies; and new cellular therapies in development for AML.

Automated summary

This review discusses the development of promising new molecular targeted approaches for AML, as well as progress in immune targeting of AML through various antibodies and cellular therapies. Despite FDA approval of new drugs for AML, it remains a major area of unmet medical need among hematologic malignancies.